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Abstract Following a myocardial infarction (MI), the immune system helps to repair ischaemic damage and restore tissue in-
tegrity, but excessive inflammation has been implicated in adverse cardiac remodelling and development towards
heart failure (HF). Pre-clinical studies suggest that timely resolution of inflammation may help prevent HF develop-
ment and progression. Therapeutic attempts to prevent excessive post-MI inflammation in patients have included
pharmacological interventions ranging from broad immunosuppression to immunomodulatory approaches targeting
specific cell types or factors with the aim to maintain beneficial aspects of the early post-MI immune response.
These include the blockade of early initiators of inflammation including reactive oxygen species and complement, in-
hibition of mast cell degranulation and leucocyte infiltration, blockade of inflammatory cytokines, and inhibition of
adaptive B and T-lymphocytes. Herein, we provide a systematic review on post-MI immunomodulation trials and a
meta-analysis of studies targeting the inflammatory cytokine Interleukin-1. Despite an enormous effort into a signifi-
cant number of clinical trials on a variety of targets, a striking heterogeneity in study population, timing and type of
treatment, and highly variable endpoints limits the possibility for meaningful meta-analyses. To conclude, we high-
light critical considerations for future studies including (i) the therapeutic window of opportunity, (ii) immunological
effects of routine post-MI medication, (iii) stratification of the highly diverse post-MI patient population, (iv) the
potential benefits of combining immunomodulatory with regenerative therapies, and at last (v) the potential side
effects of immunotherapies.
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1. Introduction
Ischaemic heart disease is estimated to account for 9 million deaths per year
and is the leading cause of global mortality.1 Importantly, 63% of myocardial
infarction (MI) patients in the UK develop heart failure (HF) within 6 years2
and90% of mortality post-MI occurs after the development of HF.3
The immune system is involved both in events leading up to an MI and
in post-MI processes and development towards HF. High levels of
systemic inflammation due to metabolic or immunological conditions
contribute significantly to an increased risk of cardiovascular disease.4,5
Post-MI, the severe tissue damage caused by an acute infarct is a potent
trigger to activate the immune system, which orchestrates the various
steps of the post-MI healing process, starting immediately with the re-
moval of cellular debris and restoration of tissue integrity. A tightly con-
trolled balance between inflammatory and regulatory mechanisms is
essential, because an inefficient early immune response may lead to fatal
cardiac rupture, while excessive inflammation may cause collateral dam-
age to healthy tissue, making both situations detrimental to healing.
Once acute inflammation has been cleared, development towards HF
may still be exacerbated by a persistent autoimmune-inflammatory con-
dition which maintains low levels of tissue damage sustaining cardiomyo-
cyte loss, fibrosis, and pathological ventricular remodelling.6
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..The clinical relevance of both pre- and post-MI inflammation has been
recognized for several decades and a wide variety of clinical trials have
attempted to target the immune system, with the majority investigating
effects on acute patient survival at a time when the immune response is
most evident. With an increased understanding of long-term immuno-
logical effects pre- and post-MI, there is growing interest in targeting the
immune system to prevent MI and HF. An immense and extensively
reviewed body of pre-clinical research7,8 supports the hypothesis that
blocking excessive inflammation has beneficial effects on MI prevention
and post-MI HF development, yet outcomes of clinical trials to date have
been varied and inconclusive as reviewed below.
In this review, we aim to provide a comprehensive overview of clinical
trials on pharmacological interventions targeting the immune system to
prevent MI or improve post-MI prognosis, from broad immunosuppres-
sive therapy to more refined approaches targeting specific pathways and
factors including reactive oxygen species (ROS), complement, mast cells,
leucocyte infiltration, inflammatory cytokines interleukin (IL)-1, tumour
necrosis factor (TNF), and IL-6, and the inhibition of adaptive B and T
lymphocytes (Figure 1). Notably, most of these therapeutics are repur-
posed anti-inflammatory and immunosuppressive agents that have been
in long-standing clinical use to prevent transplant rejection or treat
autoimmunity.
2. Systematic search strategy and
meta-analysis methods
A literature search was performed using Preferred Reporting Items for
Systematic Reviews and Meta-Analyses (PRISMA) guidelines.9 Meta-
analysis on selected trials implemented the Grading of Recommendations,
Assessment, Development and Evaluations (GRADE) tool10 endorsed by
the Cochrane collaboration. The review protocol was prospectively regis-
tered in PROSPERO.11 Briefly, a systematic literature search on immune
modulatory trials in MI, HF, and acute coronary syndrome (ACS) patients
including a proportion of ischaemia patients, was conducted using PubMed
and clinicaltrials.gov. Search terms ‘myocardial infarction’, ‘ventricular
remodelling’, ‘ischaemia reperfusion’, and ‘heart failure’ were combined
with interventions using simple Boolean operators. Placebo-controlled
clinical trials published in the last 50 years, written in English and available
as full text online were included in our review.
Despite a wide range of therapeutic strategies, only clinical trials using
IL-1 (anakinra and canakinumab) antagonists have been independently
repeated in a way allowing comparison and were selected for meta-
analysis to assess treatment efficacy. As shown in Figure 2, a total of 168
studies were identified, but only six studies met the above inclusion crite-
ria for qualitative analysis. The Cochrane risk of bias tool was used for
Figure 1 Targets of immunomodulatory clinical trials post-MI. Several underlying metabolic and immunological conditions increase a patient’s risk of suf-
fering a myocardial infarction. The immune response after a myocardial infarct is initiated through the production of ROS and the release of DAMPs from ne-
crotic cardiac tissue. This causes acute innate inflammation crucial for wound repair and the subsequent negative feedback loop to quickly dampen
inflammation. However, severe damage causes excessive inflammation and may activate the adaptive immune system, which will persist and cause ongoing
tissue damage and may exacerbate adverse remodelling towards heart failure. Clinical trials on immunomodulatory treatment after MI have targeted most
aspects of the post-MI immune response. So far the focus has been on preventing MI by targeting inflammatory and metabolic risk factors (A), early events
initiating the inflammatory cascade (B) such as ROS- and DAMP-mediated inflammation and complement-dependent damage, and on attempts to suppress
excessive inflammation (C) by blocking mast cell function, pro-inflammatory cytokines and leukocyte infiltration. Although still in the minority, some clinical
trials have also targeted B and T lymphocytes of the adaptive immune system (D).
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.the identification of any systematic error or interferences in results to be
highlighted. The primary outcome measure analysed was major adverse
cardiac events (MACE), which included mortality, incidence of HF, respi-
ratory failure, and acute kidney injury and was reported in three out of
six studies. For meta-analyses, results from the three included study
were pooled into MedCalc Version 17.5.312 and used to calculate the
risk ratios between intervention and placebo, create forest plots, and as-
sess the quality of evidence. The random effects model was implemented
using the Dersimonian Laird method.13 Random effects models (as
opposed to fixed effect models) do not assume one common treatment
effect between trials, but each included trial may have a different treat-
ment effect, and they therefore, take into account variance within trials
and between trials.14
3. The post-MI immune response as
therapeutic target: from full-blown
suppression to targeting specific
pathways
Attempts to target the post-MI immune response in clinical trials were first
made in the 1960s. Our understanding of the diverse roles of the immune
system in tissue homeostasis and the multi-dimensional crosstalk between
the immune and the cardiovascular system has increased significantly since
that time. An extensive body of pre-clinical research has started to unravel
the complex, tightly controlled temporal, and spatial interplay between im-
mune cells and factors in events leading up to MI as well as post-MI,7,15 and
it is now appreciated that targeted approaches blocking specific detrimen-
tal pathways while maintaining beneficial responses, may be the way for-
ward instead of broad immunosuppression.
3.1 Broad-spectrum immunosuppression
Early trials directed at the post-MI immune response used strong
broad-spectrum immunosuppressive drugs including corticosteroids,
methotrexate, cyclosporin A (CsA), or intravenous immunoglobulin
(IVIg). This was based on the hypothesis that all inflammation was detri-
mental for post-MI recovery.16 Table 1 compares study characteristics of
clinical trials using broadly immunosuppressive treatment post-MI.
3.1.1 Corticosteroids
Corticosteroids are in well-established clinical use to treat inflammatory
conditions such as allergies and autoimmunity. Their use post-MI was
expected to be beneficial, due to their overall suppressive effect on the
recruitment and activation of both innate and adaptive immune cells.30
However, despite pre-clinical and clinical research for over 50 years,
evidence concerning the efficacy of corticosteroids after MI is still
conflicting.
A previous systematic review with meta-analysis assessed corticoste-
roid use in 2646 patients with acute MI (AMI) in 11 trials from 1964 to
1989.16 Although corticosteroids decreased mortality by 26% compared
to placebo, this did not seem to stem from a cardio-protective effect, as
infarct size or myocardial rupture rates were unchanged. Meta-analysis
findings were limited, as most included studies were small (>_40 patients)
and little information regarding protocol and measurements had
been provided. Furthermore, very short follow-up periods (median
24.5 days) limited the possibility to assess any effects on development of
post-MI HF.
More recent results of subsequent corticosteroid trials are still con-
flicting, but due to high diversity in study populations, the varied nature
of clinical endpoints and different follow-up periods, meaningful compar-
isons are hard to draw. However, overall mortality was reported to be
Figure 2 Literature search. Flow diagram of the literature search strategy to identify clinical trials on IL-1 inhibitors suitable for meta-analysis.
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decreased in only two out of four studies performed since publication of
the previous meta-analysis. Importantly, decreased mortality was
reported in trials with slightly longer follow-up periods, while acute stud-
ies fail to show improvement. The COPE-ADHF trial (2013) reported
significant improvement in mortality with dexamethasone followed by
prednisolone treatment for 7 days in acute decompensated HF (27%
AMI). This benefit persisted over the follow up period of 1–36 months,
and the number of deaths was three in the steroid as compared with 10
in the placebo group.18 A hydrocortisone trial by Tsai et al.20 in 97 non-
randomized cardiac arrest patients also improved haemodynamics by
40%, without increased survival rates. A similar trial by Mentzelopoulos
et al.19 in which cardiac arrest patients were administered methylpred-
nisolone during cardiopulmonary resuscitation followed by hydrocorti-
sone, showed increased survival until hospital discharge, and improved
haemodynamics and organ function during a 1 year follow-up. However,
hydrocortisone did not affect cardiac shock reversal or mortality rates in
another randomized control trial by Donnino et al.17 with 50 cardiac ar-
rest patients.
3.1.2 Methotrexate
Methotrexate is another immunosuppressive drug commonly used in
clinical practice for the treatment of rheumatoid arthritis. Its mecha-
nism of action involves the release of endogenous adenosine, and
suppression of innate inflammation and the adaptive immune re-
sponse.31 The addition of methotrexate to conventional chronic HF
(CHF) therapy was supported by a small trial by Gong et al.24 in 2006
including 71 patients who received either a 7.5 mg weekly dose of
methotrexate or placebo over a 12 week period. This improved
patients’ inflammatory profile including levels of IL-6, TNF, monocyte
chemoattractant protein-1, and C-reactive protein (CRP), New York
Heart Association (NYHA) functional group, quality of life and 6 min
walk test (6MWT) distance when compared with placebo.
Conversely, the METIS trial (2009) using a similar treatment regime
in CHF patients found no improvement in 6MWT or CRP, and al-
though a trend was shown towards improved the NYHA group, dif-
ferences were not significant.23 The TETHYS trial of methotrexate
(2017) in 84 ST-Elevation MI (STEMI) patients on the other hand
showed worsened left ventricular ejection fraction (LVEF) and no re-
duction in infarct size at 3 months follow-up compared with the pla-
cebo group.21
Low-dose methotrexate is currently also being tested for its useful-
ness in the prevention of cardiovascular morbidity and mortality in 7000
patients with prior MI and Type 2 diabetes or metabolic syndrome
(Cardiovascular Inflammation Reduction Trial, CIRT).22 CIRT aims to
test the inflammatory hypothesis of atherothrombosis, which suggests
that inhibition of inflammation may reduce atherothrombosis and thus
prevent occurrence of adverse cardiovascular events.
3.1.3 Cyclosporin A
CsA inhibits antigen presentation by dendritic cells and effector T lym-
phocyte function and has been in long-standing clinical use as immuno-
suppressant to block transplant rejection.32 Notably, however, use of
CsA post-MI was attempted due to its ability to protect cardiomyocytes
from cell death due to ischaemia/reperfusion injury (I/RI). This cardio-
protective function of CsA stems from its ability to inhibit the opening
of the mitochondrial permeability transition pore (mPTP) and thereby
prevent necrotic cell death.33 A meta-analysis by Yingzhong et al.27
assessed the use of CsA in five randomized control trials of AMI
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patients, but the authors did not find any difference in all-cause mortal-
ity, LVEF, or infarct size possibly due to small sample sizes and short fol-
low-up periods. Hausenloy et al.25 found no difference in cardiac
troponin T (cTnT) levels between CsA and the placebo group in 78
elective coronary artery bypass graft (CABG) patients, over half of
which were post-MI patients. However, follow-up was only 3 days as
the focus was on peri-operative myocardial injury rather than long-term
HF development. Notably, a significant reduction in peri-operative myo-
cardial injury was observed in higher-risk patients with longer cardiopul-
monary bypass times, with CsA therapy, with a reduced post-operative
cTnT rise when compared with control. In a similar study, Chiari et al.26
found reduced cardiac troponin I (cTnI) but this change was not
reflected in patients’ clinical function 3 days after infarct.
As these trials investigated acute effects of CsA on immediate post-MI
cardiomyocyte death, follow-up periods were very short, and immuno-
suppressive effects on dendritic cell activation and effector T lymphocyte
function were not taken into account. Therefore, analysis of long-term
effects of CsA treatment on the adaptive immune response and develop-
ment of HF would be informative.
3.1.4 IVIg
IVIg is intravenously administered immunoglobulin G obtained from
pooled donor plasma. It binds to and neutralizes components of the im-
mune system which could otherwise instigate downstream inflammatory
effects. This includes necrotic debris, danger-associated molecular patterns
(DAMPs), complement, integrins, cytokines, and leucocyte receptors.34
IVIg is used clinically in a range of immunological and inflammatory diseases,
either as replacement therapy for antibody deficiencies or as immunosup-
pressive for inflammatory/autoimmune conditions.35
A potentially beneficial effect of IVIg in the context of cardiovascular
disease was first tested by Gullestad et al.29 in 40 patients with stable
CHF, 23 of which suffered from post-ischaemic damage, and LVEF was
<40%. Patients received either IVIg or placebo for 21 weeks. At
6 months follow-up, IVIg significantly up-regulated the anti-inflammatory
cytokine profile and increased LVEF by 5% compared with baseline.
However, when the same team repeated this treatment in 62 patients
with AMI following percutaneous coronary intervention (PCI), there
was no difference between the IVIg and the placebo groups.28
In summary, although broad immunosuppression by corticosteroids,
methotrexate, CsA, and IVIg are widely accepted in clinical practice as gold-
standard anti-inflammatory and immunosuppressive therapies, their use
immediately following MI remains controversial. Beneficial effects in clinical
trials are inconsistent and some studies suggest detrimental effects on the
clearance of necrotic cardiomyocytes and disrupt post-infarct healing after
AMI, causing concerns about a large risk-benefit ratio.36,37 Importantly, cur-
rently available information indicates a potentially beneficial effect of immu-
nosuppression during HF or possibly used as preventive strategy, while
treatment of AMI patients showed no effects or worsened outcomes. This
discrepancy is likely to reflect the opposing role of the immune system im-
mediately after AMI and during CHF. While the acute immune response af-
ter AMI initiates reparative processes and is essential to restore tissue
integrity, persistent inflammation and autoimmune-mediated tissue damage
may be detrimental in CHF. In addition, if events leading up to AMI are me-
diated or exacerbated by inflammation, low-dose immunosuppressive
treatment may also be beneficial in the prevention of AMI. However, if con-
sidered as long-term treatment to prevent AMI or development towards
HF, dosing of immunosuppressive regimes needs to be assessed carefully
to avoid serious adverse effects including infections and cancers.
3.2 Targeting selected pathways to achieve
immunomodulation
Recently, our understanding of the complexity of immune pathways in-
volved in early repair as well as long-term pathogenesis after MI has im-
proved significantly. The necessity of early acute inflammation and the
need for a balanced and co-ordinated response for successful healing
and functional recovery are now being appreciated. A wide range of
studies have therefore aimed to target individual pathways to modulate
the immune response towards regeneration instead of fully suppressing
the immune system.
3.2.1 Immediate post-ischaemic events
Acute I/RI injury immediately after infarct is mediated by the production
of ROS and mitochondrial dysfunction which causes necrotic cell death
and the release of DAMPs. DAMPs are intracellular molecules passively
released during myocardial necrosis and fragments of the extracellular
matrix. They include prominent examples such as hyaluronic fragments,
high-mobility group box 1, heat-shock proteins, and act as potent inflam-
matory activators for most cell types including cardiomyoctes, fibro-
blasts, endothelial cells, and immune cells.15 DAMPs can trigger
expression of pro-inflammatory cytokines and pro-hypertrophic pro-
teins, initiate cell death pathways, promote endothelial dysfunction, and
induce fibrosis.38 So far, clinical trials aiming at events immediately after
MI have targeted early inflammatory mediators such as mitochondrial
damage, as discussed above, ROS, and the complement system (Table 2).
ROS. ROS are highly reactive chemical compounds including perox-
ides, superoxide, and nitric oxide, which promote leucocyte recruit-
ment into the damaged tissue and cause further oxidative stress,
resulting in more macromolecular damage.47 This supports the use of
anti-oxidants such as N-acetylcysteine (NAC) to block ROS post-
MI48 and evidence of beneficial effects of NAC was first demonstrated
in a small trial in 27 MI patients by Arstall et al.42 Although no func-
tional changes were established by echocardiography, significantly less
oxidative stress was observed in NAC treated patients. In two other
early trials with small study populations, ISLAND (1996) and
Yesilbursa et al.,40,41 NAC treatment improved LV function and re-
duced oxidative stress post-MI. Benefits of NAC use were confirmed
by the NACIAM (2017) trial of 112 STEMI patients undergoing PCI,
which received NAC and nitrate therapy. On cardiac magnetic reso-
nance imaging (cMRI), high-dose NAC doubled myocardial salvage
from 27% to 60% and an absolute reduction in infarct size by 5.5%
compared with placebo was observed.39 However, it is impossible to
speculate about the long-term effects of this intervention, as patients
were observed only 7 days after treatment.
Decades of research and several small clinical trials now provide a
promising base for a large randomized multi-centric study, to finally
answer the question if NAC treatment is a beneficial agent to reduce re-
perfusion injury after MI. If designed with long-term effects in mind, bene-
fits related to HF development may be assessed as well. Importantly,
when interpreting NAC trial results, it also needs to be considered that
anti-oxidants affect other molecular pathways too and beneficial effects
may not be due to immunological effects only.49
Complement. The complement system is part of innate immunity and a
complex network of proteins in the blood responsible for clearance of
microbes and damaged cells. Upon reperfusion of occluded vessels, tis-
sue damage triggers complement activation leading to inflammation, and
additional tissue destruction. In particular, the classical complement
6 M. Panahi et al.
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pathway is activated and can be chronically sustained, which directly
damages the myocardium.50
C1: The C1 proteins initiate the classical complement cascade.
Inhibition of the C1 receptor using C1-INH in AMI patients given throm-
bolytic therapy showed decreased cTnT and Creatine Kinase-MB (CK-
MB) levels.45 In a study of 67 STEMI patients undergoing emergency
CABG, Thielmann et al.44 showed that C1-INH significantly reduced
C3c/C4 and cTnI levels. Similarly, in 80 STEMI patients undergoing
emergency CABG, Fattouch et al.43 described improvement in functional
measures and overall survival. Cardiopulmonary bypass support, high--
dose inotropes and time of intubation, intensive care unit stay, and in-
hospital stay were all greatly reduced in the C1-INH group.
Furthermore, these patients showed significantly improved mean arterial
pressure, cardiac index, stroke volume, and cTnI levels.
C5: C5 is part of the classical complement cascade acting downstream
of C1. A previous meta-analysis on clinical trials using pexelizumab, a
monoclonal antibody against C5, showed no improvement in outcomes
following MI, but reduced mortality in patient undergoing CABG.46
Table 2 summarizes study characteristics of trials targeting early in-
flammation post-MI by blocking ROS and complement. Although more
thorough studies are required to reach conclusive results, the above de-
scribed clinical trials provide promising results that early post-MI events
such as ROS- and complement-mediated damage may be potential tar-
gets to improve post-MI outcome. Notably, therapies targeting events
immediately after AMI are restricted by a brief window of opportunity
after initial myocardial damage or restoration of blood flow, and treat-
ment needs to be timed accurately.
3.2.2 Leucocyte infiltration
Another approach to prevent excessive inflammation and associated tis-
sue destruction post-MI is to prevent immune cells from infiltrating the
damaged tissue (Table 3). Acute damage causes local inflammation, activa-
tion of endothelial cells in the vasculature and up-regulation of adhesion
molecules such as integrins to recruit leucocytes. Neutrophils are among
the first leucocytes to migrate into the myocardium. They clear cellular de-
bris, promote macrophage infiltration, and are essential for cardiac repair
and survival.60 Canine studies showed that neutrophil depletion reduces
infarct size,61 however, post-MI neutropenia could delay cardiac repair and
preventing their infiltration is associated with decreased survival in mice.62
Integrins. Infiltration of leucocytes into damaged or inflamed tissues is
mediated by adhesion molecules on activated endothelial cells. Up-
regulation of cardiac aVb3 integrin at recently infarcted sites (measured
2 weeks after AMI) predicts improved repair and recovery in human
patients,63 and blocking P-selectin and intercellular adhesion molecule-1
(ICAM-1) in murine studies is beneficial post-MI.64 This supported the
notion that inhibition of leucocyte infiltration might improve post-MI
outcomes.
Although treatment with monoclonal antibodies against the integrin
complex CD11/CD18 has reduced infarct sizes in pre-clinical studies,
the corresponding clinical investigations in AMI patients have not been
encouraging. The LIMIT-AMI study (2001) targeted CD18 in a study of
394 patients, but did not find any difference in coronary blood flow, in-
farct size, or the rate of ECG ST-segment elevation resolution.53
Similarly, the FESTIVAL study (2001) tested a monoclonal antibody
against CD11/CD18 in 60 patients following coronary angioplasty and
did not find any difference in infarct size at 30 day follow-up.52 There was
also no improvement in infarct size measured 5–9 days following an anti-
CD11/CD18 receptor antibody at either high or low dose in a 420
participant study in the HALT-MI (2002) investigation.51 These studies
all measured infarct size or flow rate as primary outcomes. A trial mea-
suring effects of anti-CD11/CD18 treatment on heart function would be
informative.
Mast cells. The number of cardiac mast cells increases dramatically fol-
lowing MI, along with macrophages, and they influence the inflammatory
process via histamine, growth factor, and cytokine release.65 They also
induce fibroblast differentiation and modulate myocardial tissue healing
and formation of the infarct scar.66
Tranilast is an anti-fibrotic drug which prevents collagen synthesis by
inhibiting the release of mast cell factors, including histamine, and prosta-
glandins.67 Two early trials (TREAT and TREAT 2) showed that 600 mg
tranilast daily for 3 months caused a significant reduction in restenosis re-
quired for non-stented patients. On angiography, the TREAT trial (1999)
reported a restenosis rate of 14.7% compared with 46.5% in the placebo
group, and 18.8% compared with 44.1% in the TREAT-2 trial (2002).55,56
However, the PRESTO trial (2002) failed to show any improvement in
quantitative measures of restenosis as measured by angiography and in-
travascular ultrasound in 11 484 patients treated with tranilast twice
daily for 1 or 3 months, 4 h following PCI. There was no difference to pla-
cebo treatment in mortality, MI, or ischaemia-driven target vessel re-vas-
cularization in the 9 month follow-up.54
Histamine released by cardiac mast cells acts on two distinct histamine
receptors type 1 and 2 (H1R and H2R), which increase endothelial per-
meability and exacerbate ischaemia/reperfusion injury I/RI, resulting in in-
creased infarct size.68,69 A small single-blind trial by Mujtaba et al.57 with
60 STEMI patients prescribed 40 mg daily H2R antagonist famotidine
upon hospital admission showed reduced LV dilation. However, LVEF
was also decreased on echocardiography when followed up at day 30.
Another trial by Kim et al.58 on 318 CHF patients, who received 30 mg
famotidine daily for 6 months, showed reduced ventricular remodelling
with a reduction in LV end-diastolic and end-systolic diameters, lower
brain natriuretic peptide (BNP), and decreased NYHA functional class.
Conversely however, a small study on 12 patients by Lucas et al.59 using
three H2R antagonists (H2RA) cimetidine, famotidine and ranitidine ad-
ministered for 7 days did not improve metabolic or exercise perfor-
mance or LVEF upon echocardiography compared with placebo in
NYHA Class II/III patients.
Thus far, clinical trials using early leucocyte accumulation as thera-
peutic target have included non-specific blocking of leucocyte migra-
tion by inhibiting the integrin complex CD11/CD18 and blocking of
mast cell effector functions (Table 3). While the first approach has not
yielded any beneficial effects, targeting mast cells seems a promising
avenue worth exploring further. Importantly, as for ROS and comple-
ment targeting strategies, treatments need to be administered at the
best time to suppress excessive infiltration, while maintaining healing
responses and beneficial cardiac remodelling. This likely means a delay
of immunomodulatory treatment of 2–3 days to maintain acute neu-
trophil and monocyte infiltration to support the initiation of the heal-
ing process, while blocking persistent infiltration and excessive
accumulation within the tissue once the acute response should be
cleared.
3.2.3 Adaptive immunity
MI not only triggers acute early inflammation, but also a substantial adap-
tive immune response against cardiac self-proteins. Due to the immuno-
logical memory of adaptive immune cells, this auto-reactivity in form of
self-reactive T and B lymphocytes and auto-antibodies lingers, and has
8 M. Panahi et al.
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been suggested to cause ongoing tissue destruction, exacerbating the
risk of developing HF.
T lymphocytes. Pre-clinical studies have shown that T lymphocytes ac-
cumulate in the infarct zone within minutes following I/RI and that CD4þ
T lymphocytes contribute to additional tissue injury.70
As discussed above, CsA was used as experimental post-MI treatment
due to its role in blocking mPTP opening, and was therefore, expected
to reduce mitochondrial dysfunction and cardiomyocyte death immedi-
ately after AMI. However, CsA also targets calcineurin to inhibit the tran-
scription of IL-2, IL-4, and CD40, cytokines and co-receptors important
for effector T lymphocyte recruitment and function.71 Trials performed
so far did not find any difference in cardiac damage as measured by
cTnT levels, LVEF, infarct size, or all-cause mortality three days after in-
farct.25–27 These studies focused on the effects of CsA administration im-
mediately after infarct. However, the adaptive immune system remains
active long-term after MI. Therefore, considering that all-cause mortality
did not change and CsA treatment was deemed safe, longer treatments
and in particular longer follow-up periods may be worthwhile to investi-
gate any long-term effect on cardiac remodelling and function.
The pro-inflammatory activity of effector T lymphocytes and other in-
flammatory immune cells is counterbalanced by the regulatory arm of
the immune system, most prominently by T regulatory (Treg) cells.
Experimental studies indicate an important role of Treg cells in improv-
ing post-MI tissue regeneration by modulating the function of other leu-
cocytes.72 Treg cells have anti-inflammatory properties which promote
skeletal muscle regeneration, and might therefore, also establish a pro-
regenerative environment in the heart. Boosting the Treg cell population
has been proven beneficial in a variety of inflammatory settings and might
be a therapeutic avenue worth exploring in post-MI patients.73
Adenosine, a naturally occurring nucleoside increases Treg cell num-
bers,74 and although the rationale for its use post-MI was to protect car-
diomyocytes from acute I/RI, it has also been shown to reduce infarct
size in pre-clinical studies by suppressing CD4þeffector T lymphocyte
subsets.70 A meta-analysis of 15 randomized-controlled trials involving
1736 patients with AMI undergoing PCI reported a reduction in HF de-
velopment with adenosine use, but there was no overall improvement in
LVEF or survival.75 Confirmation of any effects on the adaptive immune
system would be informative. No clinical trials specifically targeting the
Treg cell population have been performed yet.
B lymphocytes. DAMPs and damaged myocardial tissue activate circu-
lating CD20þB lymphocytes. These selectively produce the chemokine
CCL7, which causes inflammatory monocytes to migrate from the bone
marrow into the circulation. High circulating levels of CCL7 and B cell
activating factor (BAFF) were associated with higher rate of mortality in
patients with recurrent MI. Antibody-mediated depletion of CD20 or
BAFF in experimental MI models reduced inflammatory recruitment and
improved cardiac function.76
Rituximab is an anti-CD20 antibody used clinically to treat inflamma-
tory autoimmune diseases and B lymphocyte cancers. The RITA-MI
study is currently recruiting participants to test its clinical efficacy and
safety in AMI.77
3.2.4 Inflammatory cytokines
A long list of cytokines and chemokines has been implicated in post-MI
inflammation, but the best studied cytokine targets post-MI to date are
IL-1, IL-6, and TNF. Study characteristics for clinical trials on cytokine in-
hibition are shown in Table 4.
Interleukin-6. IL-6 may have both pro- and anti-inflammatory proper-
ties and can activate the PI3K pathway, which is associated with adaptive
hypertrophy and protects cardiomyocytes from apoptosis.94,95 IL-6 lev-
els post-MI correlate with increased CRP production, which is a predic-
tor of progression and future risk of coronary heart disease.96
Tocilizumab is an IL-6 receptor antagonist used as anti-inflammatory
therapy for rheumatoid arthritis.97 A recent study by Kleveland et al.85
in 117 non-ST elevation MI (NSTEMI) patients undergoing coronary
angiography showed significantly lower levels of high-sensitivity
CRP (hs-CRP) and cTnT after tocilizumab administration over 3 days
hospitalization. This was particularly substantial in acutely treated
patients and during percutaneous PCI, which suggests cardio-protective
potential during I/RI. A subsequent study by Holte et al.84 found no differ-
ence in coronary flow reserve (CFR), as a reflection of endothelial func-
tion, in these patients over 6 months follow-up, suggesting tocilizumab
influences systemic inflammation as measured by CRP, not coronary en-
dothelial function. The recent STAT-MI trial ended early as futility analy-
sis showed low likelihood of reaching the primary outcome, with
authors attributing early termination to insufficient subject recruitment.
The results for 28 patients showed no significant change in MACE, CRP,
or ECG.86,98
Interleukin-1. IL-1a is a cytokine released from necrotic cardiomyo-
cytes and acts as a danger signal triggering acute inflammation and healing
following MI.99 IL-1b is released by activated leucocytes within hours
post-MI and has been implicated in leucocyte infiltration and ventricular
remodelling.100,101 Importantly, pre-clinical data showed that antibody-
mediated IL-1b neutralization reduced post-MI inflammation, adverse
remodelling, and HF in mice.102,103
Anakinra is a recombinant competitive non-specific IL-1 receptor
antagonist (IL-1RA) and has been used for the treatment of rheuma-
toid arthritis.104 Clinical trials using anakinra have shown significant
down-regulation of systemic inflammation as measured by CRP in
acute decompensated HF,79 NSTEMI ACS80 and AMI.82 Sonnino
et al.81 also reported decreased IL-6 levels 3 months after anakinra
treatment in AMI. In a small pilot study, Abbate et al.82 randomized 10
patients to either anakinra or placebo. Over a 10–14 week follow up
period, improvements in LV remodelling with a drop in LV end-sys-
tolic volume index (LVESVi) were measured by cMRI. However, large
and adequately powered studies are required to assess the safety and
efficacy of anakinra, as Van Tassell et al.79 did not show a reduction in
MACE up to two weeks after treatment with anakinra in 30 HF
patients and another study (Morton et al.80) showed increased
markers of inflammation and re-infarct rates following discontinuation
of anakinra.
Canakinumab is a monoclonal antibody that specifically neutralizes the
pro-inflammatory effects of IL-1b.105 Ridker et al.83 tested canakinumab
treatment in 556 type-2 diabetes patients at high risk of MI and found an
improvement in overall inflammatory measures. Recently the CANTOS
trial (2017) studied the effect of canakinumab in 10 061 patients with
previous MI and raised CRP levels. Canakinumab significantly reduced
CRP levels compared with placebo, and it also significantly lowered the
incidence of recurrent non-fatal MI, non-fatal stroke, and cardiovascular-
related death after 2 years follow-up.78
The above studies were analysed for their risk of bias profiles
(Figure 3A). In two studies, we identified ‘other bias’, which is defined as
‘sources of bias relevant only in certain circumstances or not covered by
the other headings’. Sonnino et al. (2014) was classified as such because
studies were performed on ex vivo peripheral blood leucocytes.81
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Abbate et al. (2010) was excluded, because it was a small pilot study with
only 10 patients with a greater risk of strong impact by outliers.82 Both
studies, as well as Ridker et al. (2012) did not measure MACE, so were
excluded from meta-analysis.83 The three remaining trials measured
MACE and were included in meta-analysis.78–80 Of 10 273 patients, 30
were classified as HF and 10 243 as high risk of HF. The risk ratio (RR)
and confidence intervals (CIs) for mortality and MACE were calculated
as 1.07 (0.52–2.22) showing that overall mortality and MACE in the
treated groups was not decreased compared to the placebo groups
(Figure 3B). However, these studies still present a significant heterogene-
ity in study design and population (secondary prevention in patients at
high risk of MI, HF, or ACS patients) and tested drug (canakinumab or
anakinra).
The CANTOS study was still a major step forward investigating a
more targeted approach to immunomodulation following MI. It was
however, primarily focused on preventing atherosclerosis and results
are assumed to be due to a reduction of systemic inflammation, and sub-
sequently less thrombosis-mediated cardiovascular events.
Measurements of cardiac functional or morphological parameters would
have allowed a conclusion about direct effects on the heart.
TNF. TNF promotes leucocyte infiltration by up-regulating transcription
of adhesion molecules and chemokines. However, TNF also demon-
strates pleiotropic effects in delaying myocyte apoptosis following acute
ischaemia.106 Etanercept is a high affinity TNF receptor which has been li-
censed for treatment of rheumatoid arthritis.107 A small early study of
etanercept by Deswal et al.93 given to 12 HF patients appeared to im-
prove ejection fraction and 6MWT performance over placebo control
subjects. In another study by Fichtlscherer et al.,92 etanercept treatment
of 13 CHF patients seemed to increase endothelium-dependent forearm
blood flow as compared with 5 control patients, but not endothelium-
independent, suggesting improvement in systemic endothelial vasoreac-
tivity. Bozkurt et al.91 performed a trial using biweekly subcutaneous
injections of etanercept 5 mg/m2 (n= 16) or 12 mg/m2 (n= 15) or with
placebo (n= 16) for 3 months in patients with NYHA Class III to IV HF
and showed dose-dependent improvement in LV structure and function,
with improved NYHA class when compared to placebo.
During the RECOVER and RENNAISANCE studies, NYHA Class III
to IV CHF patients received placebo (n= 373) or 25 mg of etanercept
once, twice, or three times per week (n= 375 each group). No clinical
or survival improvements were observed after nearly 2 years, and there-
fore, both studies were prematurely terminated.88 Joint analysis
(RENEWAL) of both trials rules out a clinically relevant benefit of eta-
nercept on the rate of death or hospitalization due to CHF.89
A final trial using etanercept by Padfield et al.,87 in a 26 patient AMI
study also failed to show beneficial clinical effects and found that in fact
reductions in neutrophil and IL-6 levels correlated with increased plate-
let and monocyte activation.
Another TNF inhibitor, the chimeric monoclonal antibody infliximab,
was used at 5 or 10 mg/kg at 0, 2, and 6 weeks in a trial on 150 patients
with moderate-to-severe HF, but no improvement in clinical status was
observed despite suppression of inflammatory markers CRP and IL-6.
However, there was a higher ratio in adverse effects noted in the 10 mg/
kg infliximab group.90
The original rationale behind targeting inflammatory cytokines as
preventive strategy as well as post-MI stems largely from the emerg-
ing concept of atherosclerosis as an inflammatory disease.
Preventing an exacerbation of atherosclerosis by targeted anti-
inflammatory treatments, previously shown to be effective in sys-
temic autoimmune disease, was anticipated to protect from recur-
rent cardiovascular events. Importantly however, besides decreasing
systemic inflammation, studies on IL-1 receptor antagonist anakinra
suggest the potential for effects on heart tissue function and remod-
elling.82 This allows a first promising glimpse into the potential bene-
fit of these therapies in protecting from adverse remodelling and
development of HF post-MI.
4. Considerations for future
research and trial design
An enormous amount of effort and resources has gone into a wide range
of immunomodulatory trials (Figure 1), which have accumulated a wealth
of invaluable information to allow future trials to be designed in the
most efficient way. Yet to date, practical challenges dealing with a highly
diverse post-MI patient population, and striking heterogeneity in trial de-
sign means evidence available in support of immunomodulatory
P
P
Figure 3 Meta-analysis of clinical trial outcomes of IL-1 inhibitors. (A) Risk of bias summary: review authors’ judgement about each risk of bias item for
each included study. (B) Forest plot showing proportions of mortality rates, RR and 95% CIs for trials of IL-1 inhibition in MI and HF. The random effects
model was used, and RR was determined using the DerSimonian–Laird method.
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treatment is still inconclusive. We recommend consideration of the fol-
lowing factors to achieve standardization in the design of future clinical
trials.
4.1 Therapeutic strategy and target
Due to the dynamic nature of the post-MI immune response, small varia-
tions in exact target, timing, and dosage can lead to tremendous differen-
ces in the effect on the immune response. In addition, both pre-MI and
early post-MI clinical situation affect long-term complications, including
the development towards HF. Early and late phase post-MI should there-
fore not be looked at in isolation. When interpreting the currently avail-
able information on immunomodulation trials, it is crucial to discriminate
between studies on pre-MI prevention, AMI recovery, or CHF mortality.
Most trials so far have focused on AMI, thus investigated early effects
only. Future trials need to carefully consider the best time point for drug
administration to optimize acute infarct healing and long-term functional
recovery.
4.2 Routine medication/therapy
Currently used routine post-infarct medication affect the immune re-
sponse, and this may have significant impact on experimental treatments
and may result in unexpected outcomes if routine treatment is changed.
There are several prominent examples of routine medication with either
pro- or anti-inflammatory effects. Platelet inhibitors such as aspirin and
clopidogrel attenuate platelet-leucocyte interaction, thus suppress ROS
formation, leucocyte activation, and expression of pro-inflammatory
cytokines.108,109 Statins, which are still used to block the production of
low-density lipoprotein (LDL) cholesterol, down-regulate effector T
lymphocytes, while increasing expression of Treg cell markers, IL-10, and
tumour growth factor-b (TGF-b).110 On the other hand anti-
hypertensive beta-blockers such as metroprolol and propranolol reduce
IL-10 and TGF-b levels111 and information on the immunological effects
of vasodilators such as angiotensin conversing enzyme inhibitor (ACEi)
has been conflicting.112 Accordingly, depending on standard treatment
regime, immunomodulatory therapy may be hampered or boosted.
4.3 Patient population
Trial results also hint towards the need of a stratified approach to immu-
nomodulatory care of post-MI patients, as some patient groups may re-
spond and benefit significantly more than others. The post-MI
population is strikingly heterogeneous and the risk of poor outcome and
development to HF is influenced by several factors including demo-
graphics, genetics and pre-existing immunological, and metabolic condi-
tions.113 It seems feasible that immunomodulatory treatment may be
most beneficial for patients with a raised inflammatory profile and the
CANTOS trial has indeed provided first evidence for this hypothesis.78
4.4 Combination therapy
While the immune response is certainly a crucial player in post-MI
wound closure and restoration of tissue integrity, its modulation will
likely only prevent ongoing damage rather than replacing tissue already
lost. Long-term benefits on heart function are more likely to be achieved
if immunomodulation is combined with regenerative therapies such as
biomaterial-based strategies or cell therapies aiming to replace damaged
cardiomyocytes. Combination therapy will not only prevent ongoing
damage, but also provide therapies with a local environment permissive
of regeneration.6 Numerous studies have been undertaken in recent
years to evaluate the effect of stem cell mobilization, recruitment or
transplantation into the myocardium.114,115 One approach particularly
interesting in this context is the use of mesenchymal stem/stromal cells
(MSC). MSC themselves combine cell therapy with immunomodulation
due to their stem cell-like and immunosuppressive characteristics.
Although it has become clear that their initially assumed immunoprivi-
lege may be lost upon differentiation, a Phase I/II randomized comparison
(POSEIDON study) of trans-endocardial injection of MSCs in patients
with LV dysfunction showed positive effects on functional capacity, qual-
ity of life, and ventricular remodelling.116 Once both immunomodulatory
strategies and cardiac regenerative cell therapy have overcome current
hurdles, the combination might be able to achieve astonishing results.
4.5 Complications of immunotherapies
Cost-benefit ratios and incidence of severe side effects need to be care-
fully considered and investigated before administration of post-MI immu-
notherapies. A tightly regulated balance between immune activation and
regulation ensures efficient responses against infections and cancers,
while preventing autoimmunity. Suppressing all or part of the immune
system post-MI may impact on wound healing and regenerative pro-
cesses in other areas of the body, weaken defences against infectious dis-
eases, and undermine the ability of the immune system to detect and
destroy malignant growth early on. Chronic immunosuppressive treat-
ment using methotrexate, cyclosporine, or anti-TNF reagents is known
to carry an increased risk of lymphoma, due to decreased immunesur-
veillance.117 Importantly however, these potentially serious complica-
tions need to be assessed for individual treatments and will depend on
the specific role of the immunomodulation target in the relevant settings.
For example, IL-1b inhibition with canakinumab during the CANTOS
trial reduced the incidence of lung cancer and lung cancer mortality,
while fatal infections and sepsis were more common in the canakinumab
treated group.118
5. Recommendations for
standardization of future post-MI
immunomodulatory trials
5.1 Start of treatment
To ensure the initiation of an appropriate wound healing response, ad-
ministration of strong immunosuppressive treatment within 24 h after
AMI should be avoided. Two to 3 days post-MI may be a more beneficial
time point causing less adverse effects. This may be hard to achieve with
strategies targeting events or factors immediately post-MI (e.g. ROS,
complement). Notably, due to its effects on the adaptive immune sys-
tem, CsA which has been used safely (albeit without clinical effects) at
early time points, with the aim to prevent immediate post-MI cardiomyo-
cyte death, may be a worthwhile candidate to explore for its long-term
effects on HF development. Trials targeting mast cells have also yielded
promising results and they may benefit from a wider therapeutic win-
dow, allowing treatment to be delayed for a few days post-MI.
So far, the maybe greatest patient benefit of immunomodulatory
treatment was achieved by IL-1 inhibition (CANTOS trial) in previous
MI patients with raised inflammatory profiles, thus at greater risk of de-
veloping subsequent MIs or HF. Due to the delay post-MI, this patient
population was likely beyond the acute phase of wound healing and inhi-
bition of a potent inflammatory mediator successfully decreased sys-
temic inflammation without affecting early healing.
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5.2 Outcome measures
Besides MACE, outcome measures to allow an assessment of both acute
and long-term benefits of immunomodulatory treatment should include
functional and morphological measurements such as LV ejection fraction
and diameters as assessed by echocardiography or MRI. Importantly,
these should be obtained at baseline and at defined time points following
AMI (e.g. 1 month, 3 months, 1 year, 2 year, and 4 year following MI).
Considering that 63% of MI patients develop HF within 6 years post-MI,2
shorter follow up periods will not allow to judge if the treatment affects
development towards HF. Incorporating measurement of CRP and BNP
or NT-pro BNP will help identify patients’ response to therapies and
identify patients at risk of overt immune suppression. Measuring adaptive
immune auto-reactivity against the heart (e.g. serum auto-antibody lev-
els) would further improve our understanding of the immunological fac-
tors involved in post-MI HF development.
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